ProCE Banner Activity


Improving the Co-management of Moderate to Severe Pediatric and Adult Atopic Dermatitis in Primary Care and Specialty Settings

Virtual Roundtable

Atopic dermatitis (AD) is a chronic inflammatory disorder affecting millions of pediatric patients and, oftentimes, continuing into adulthood. When left untreated, moderate to severe AD is associated with significant morbidity and a wide range of comorbid conditions. In recent years, new and emerging therapies have greatly expanded therapeutic options available to healthcare professionals. Tune in to this dynamic roundtable webcast as specialist and primary care clinicians discuss strategies to improve care coordination and co-management of AD to optimize patient and disease outcomes.

Nurses/Nurse Practitioners: 1.00 NAPNAP contact hour, including 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: June 10, 2022

Expiration: June 09, 2023

No longer available for credit.



Victoria Garcia-Albea

Victoria Garcia-Albea, PNP, DCNP, MSN, BSN, PRN

Lahey Dermatology Nurse Practitioner Training Program
Lahey Hospital and Medical Center
Burlington, Massachusetts

Tracey M. Piparo

Tracey M. Piparo, PA-C

Physician Assistant
Division of Palliative Medicine
RWJ Barnabas Health
New Brunswick, New Jersey
Immediate Past President
New Jersey State Society of Physician Assistants
Allentown, New Jersey

Jonathan I. Silverberg

Jonathan I. Silverberg, MD, PhD, MPH

Associate Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC


This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Provided by

ProCE Banner
ProCE Banner


Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc

Sanofi Genzyme

Target Audience

Dermatology, primary care, and pediatric NPs and PAs

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply treatment options based on the stepwise management approach for AD in pediatric and adult patients

  • Incorporate a co-management approach with shared decision-making into patient and caregiver encounters

  • Select appropriate therapies for pediatric and adult patients with moderate to severe AD based on patient- and disease-related factors and the efficacy and safety of available therapies


All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Victoria Garcia-Albea, PNP, DCNP, MSN, BSN, PRN: consulting fees: Sanofi-Genzyme.

Tracey M. Piparo, PA-C, has no relevant financial relationships to report.

Jonathan I. Silverberg, MD, PhD, MPH: consulting fees: AbbVie, Afyx, Aobiome, Arena, Asana, Aslan, BioMX, Biosion, Bluefin, Bodewell, Boehringer Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Luna, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi, Shaperon, Sidekick Health; fees for non-CME/CE services: AbbVie, Eli Lilly, Leo, Pfizer, Regeneron, Sanofi; funds for research support (paid to institution): Galderma, Pfizer.

None of the members of the Planning Committee, NAPNAP staff, or PCE staff have any relevant relationships to disclose.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete the evaluation form

Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 67%.

The estimated time to complete this activity is 1.00 hour.

Release date: June 10, 2022
Expiration date: June 9, 2023


Video Roundtable


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.


NAPNAP CE Contact Hours Designation

This program is accredited for 1.0 NAPNAP CE contact hours of which 1.0 contain pharmacology (Rx) content, per the National Association of Pediatric Nurse Practitioners Continuing Education Guidelines.

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until June 9, 2023. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Additional Information

Program Medium

This program has been made available online.